Precision Medicine

AI is steadily reshaping healthcare with promising advances, but significant challenges to broader adoption still must be overcome.

The Los Angeles-based health system is looking to build and scale personalized medicine, specialty care, hospital workflow and clinical decision support systems using artificial intelligence.

They're used to forecast the longitudinal behavior of trial participants – and by predicting individuals' likely response to a drug, can improve data quality and shorten trial timelines, says Unlearn CEO Steven Herne.

Amprion has partnered with Mayo Clinic Laboratories to expand access to its test, which detects misfolded proteins associated with Parkinson’s, Lewy body dementia, and multiple system atrophy. Russ Lebovitz, the company's CEO, explains.

Mariam AlEissa, adjunct assistant professor at Alfaisal University in Saudi Arabia, explains how genomics data can identify causes of, and help develop treatments for, non-communicable diseases.

Clinical pathways provide evidence-based treatment guidance that supports standardization of care. In a roundtable and webinar, sponsored by Elsevier's ClinicalPath, oncology leaders and pathway experts discussed the benefits and appropriate use of clinical pathways in oncology. This report presents valuable insights from those discussions.  

It has also revealed ongoing work applying AI to track medical resource utilisation in real time.

The health system is establishing a new center for artificial intelligence to enhance diagnostics, personalize treatments and optimize healthcare delivery for adolescents – and plans to implement clinical trials at the Kravis Children’s Hospital.

Also, DrFirst earns HITRUST for electronic prior authorization, e-prescribing, patient engagement and other healthcare tools.

Genomics CEO Sir Peter Donnelly believes genome testing will become routine within 10 years, leading to lives saved.